Dr. David Reigada Prado has a Biology degree (1997) and a PhD in Biology (2002; University of Barcelona, Spain), which were gained under the supervision of Dr. Solsona, while studying biophysics of neurotransmitter release. In 2002, his first postdoctoral position was at the Dr. Mitchell's group in the Physiology Department of the University of Pennsylvania (Philadelphia, USA. 2002-2006) where he studied the involvement of the purinergic system in the aetiology of glaucoma. Then, he joined the group of Dr. de Ceballos in the Cajal Institute (Madrid, Spain. 2007-2008), studying the involvement of the endocannabinoids in the treatment of Alzheimer´s disease. From 2009, he has been a Senior Post-Doc Researcher in the Molecular Neuroprotection Group at the National Hospital of Paraplegics (Toledo, Spain) under the direction of Dr. M. Maza. There, he searches for strategies for the early treatment of neurotraumatic damage after a spinal cord injury, including the neuroprotective roles of XIAP protein, the purinergic system or microRNAs.